New asthma injection shows promise in early trial
NCT ID NCT06911866
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called RC1416 in 40 adults with moderate to severe asthma. Participants received a single injection of either the drug or a placebo. The main goal was to check safety and how the body processes the drug, with a preliminary look at whether it helps control asthma. Results will guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RC1416 injection
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe asthma that is not well controlled by current therapies.
What could go wrong
This is an early Phase 1b study with only 40 participants, focused mainly on safety and dosing. It is too small and early to know if RC1416 will actually improve asthma symptoms or be better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
-
Hebei Petro China Centre Hospital
Langfang, Hebei, China
-
Hebei Province Hospital of Chinese Medicine
Shijiazhuang, Hebei, China
-
Jining NO.1 people's hospital
Jining, Shandong, China
-
Liaocheng People's Hospital
Liaocheng, Shandong, China
-
Nanjing First Hospital
Nanjing, Jiangsu, China
-
Nanyang Central Hospital
Nanyang, Henan, China
-
Peking University Shougang Hospital
Beijing, Beijing Municipality, China
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
-
The First Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
-
Xinxiang First People's Hospital
Xinxiang, Henan, China
-
Zibo Municipal Hospital
Zibo, Shandong, China